smpСкорая медицинская помощьEMERGENCY MEDICAL CARE2072-6716Northwest State Medical University named after II Mechnikov10.24884/2072-6716-2019-0-3-62-67smp-367Research ArticleОБЗОРЫREVIEWSОСТРЫЙ КОРОНАРНЫЙ СИНДРОМ: ЧТО ИЗМЕНИЛОСЬ В НАШИХ ПРЕДСТАВЛЕНИЯХ О ПАТОГЕНЕЗЕ И ПОДХОДАХ К ЛЕЧЕНИЮ? (ЧАСТЬ II)ACUTE CORONARY SYNDROME: A SEA CHANGE IN OUR UNDERSTANDING OF PATHOGENESIS AND WAY OF TREATMENT? (PART II)ШальневВ. И.ShalnevV. I.

Шальнев Владимир Ильич — доктор медицинских наук, профессор кафедры скорой медицинской помощи

191015, Санкт-Петербург, Кирочная ул., д. 41

Vladimir I. Shalnev  

Visszgmu@yandex.ruСеверо-Западный государственный медицинский университет им. И. И. МечниковаРоссияNorth-Western State Medical University named after I. I. MechnikovRussian Federation2019221220192036267Copyright © Шальнев В.И., 20192019Шальнев В.И.Shalnev V.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://smp.spb.ru/jour/article/view/367

Во второй части обзора обсуждается роль остаточного липидного и тромботического рисков у больных ИБС и возможности их коррекции. Анализируются результаты ряда крупных международ­ных клинических исследований, посвященных роли нового класса гиполипидемических препаратов (ингибиторов PCSK‑9) в лечении ИБС, проведенных в последние годы. Обсуждаются новые клиниче­ские рекомендации Европейского общества кардиологов по лечению острого коронарного синдрома.  

The second part of review highlights the role of residual lipid and thrombotic risks in coronary heart disease patients and possible ways of its correction. The results of randomized clinical trials dedicated to the efficacy of new class of hypolipidemic drug (PCSK‑9 inhibitors) in acute coronary syndrome setting are discussed. Recently published new guidelines of European Society of Cardiology on acute coronary syndrome management are also highlighted.  

острый коронарный синдромдислипидемиятромбозacute coronary syndromedislipidemiathrombosisReferencesШальнев В. И. Острый коронарный синдром: что изменилось в наших представлениях о патогенезе и подходах к лечению? (Часть I) // Скорая медицинская помощь. 2019. № 2. С. 67–74.Shalnev V. I. Chto izmenilos v nashih predstavleniyah o patogeneze I podhodah k lecheniyu. Skoraya meditsinskaya pomosh, 2019, No 2, pp. 67–74 (in Russ.).Lu Y., Zhou S., Dreyer R. P. et al. Sex differences in inflammatory markers and health status among young adults with acute myocardial infarction: Results from the VIRGO study // Circulation Cardiovasc. Qual. Outcomes. 2017. Vol. 10 (2). e003470.Lu Y., Zhou S., Dreyer R. P. et al. Sex differences in inflammatory markers and health status among young adults with acute myocardial infarction: Results from the VIRGO study // Circulation Cardiovasc. Qual. Outcomes. 2017. Vol. 10 (2). e003470.Bohula E. A., Giugliano R. P., Cannon C. P. et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT // Circulation. 2015. Vol. 132. P. 1224–1233.Bohula E. A., Giugliano R. P., Cannon C. P. et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT // Circulation. 2015. Vol. 132. P. 1224–1233.Шальнев В. И. Влияние раннего применения симвастатина на уровень С реактивного белка, липиды крови и клиническое течение при остром коронарном синдроме // 2007. № 11. С. 46–50.Shalnev V. I. Vliyanie rannego primeneniya simvastatina na uroven C reaktivnogo belka, lipidi krovi i klnicheskoe techenie pri ostrom koronarnom sindrome. Klinicheskaya meditsina, 2007, No 11, pp. 46–50 (in Russ.)Шальнев В. И., Мазуров В. И. Эффективность и безопасность максимальных доз статинов при остром коронарном синдроме // Кардиология – реалии и перспективы: материалы Российского национального конгресса кардиологов. М., 2009. С. 391.Shalnev V. I., Mazurov V. I. Effektivnost I bezopasnost maksimalnih doz statinov pri ostrom koronarnom sindrome. Kardiologiya – realii i perspektivy: materialy Rossijskogo nacional’nogo kongressa kardiologov. Moscow, 2009, р. 391. (in Russ.).Шальнев В. И. Влияние различных режимов ранней терапии статинами на динамику липидов крови при остром коронарном синдроме // Скорая медицинская помощь. 2011. № 3. С. 70–76.Shalnev V. I. Vliyanie razlichnih regimov ranney terapii statinami na dinamiku lipidov krovi pri ostrom koronarnom syndrome. Skoraya meditsinskaya pomosh, 2011, No 3, pp. 70–76 (in Russ.).Toth P. P., Patti A. M., Giglio R. V. et al. Management of Statin Intolerance in 2018: Still More Questions Than Answers // Am. J. Cardivascular Drugs. 2018. Vol. 18 (3). P. 157–173.Toth P. P., Patti A. M., Giglio R. V. et al. Management of Statin Intolerance in 2018: Still More Questions Than Answers // Am. J. Cardivascular Drugs. 2018. Vol. 18 (3). P. 157–173.Gugliano R. P., Sabatine M. S. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? // J. Am. Coll. Cardiol. 2015. Vol. 65. P. 2638–2651.Gugliano R. P., Sabatine M. S. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? // J. Am. Coll. Cardiol. 2015. Vol. 65. P. 2638–2651.Sabatine M. S., Gjugliano R. P., Keech A. C. et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease // New Engl. J. Med. 2017. Vol. 376. P. 1713–1722.Sabatine M. S., Gjugliano R. P., Keech A. C. et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease // New Engl. J. Med. 2017. Vol. 376. P. 1713–1722.Schwartz G. G., Bessac L., Berdan L. G. et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial // Am. Heart J. 2014. Vol. 168. P. 682–689.Schwartz G. G., Bessac L., Berdan L. G. et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial // Am. Heart J. 2014. Vol. 168. P. 682–689.Schwartz G. G., Steg P. G., Szarek M. et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome // New Engl. J. Med. 2018. Vol. 379. P. 2097–2107.Schwartz G. G., Steg P. G., Szarek M. et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome // New Engl. J. Med. 2018. Vol. 379. P. 2097–2107.Pradhan A. D., Aday A. W., Ridker P. M. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy // Circulation. 2018. Vol. 138. P. 141–149.Pradhan A. D., Aday A. W., Ridker P. M. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy // Circulation. 2018. Vol. 138. P. 141–149.Ridker P. M., Revkin J., Amarenco P. et al. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients // New Engl. J. Med. 2017. Vol. 376. P. 1527–1539.Ridker P. M., Revkin J., Amarenco P. et al. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients // New Engl. J. Med. 2017. Vol. 376. P. 1527–1539.Roffi M., Patrono C., Collet J. P. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology // Eur. Heart J. 2016. Vol. 37 (3). P. 267–315.Roffi M., Patrono C., Collet J. P. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology // Eur. Heart J. 2016. Vol. 37 (3). P. 267–315.Ibanez B., Agawall S., Antunes M. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST segment elevation of the European Society of Cardiology // Eur. Heart J. 2018. Vol. 39. P. 119–177.Ibanez B., Agawall S., Antunes M. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST segment elevation of the European Society of Cardiology // Eur. Heart J. 2018. Vol. 39. P. 119–177.Valgimigli M., Bueno H., Byrne R. et al. 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). The Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology // Eur. Heart J. 2018. Vol. 39. P. 213–260.Valgimigli M., Bueno H., Byrne R. et al. 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). The Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology // Eur. Heart J. 2018. Vol. 39. P. 213–260.Libby P., Pasterkamp G. Requiem for the “vulnerable plaque” // Europ. Heart J. 2015. Vol. 36. P. 2984–2987.Libby P., Pasterkamp G. Requiem for the “vulnerable plaque” // Europ. Heart J. 2015. Vol. 36. P. 2984–2987.Stone G. W., Maehara A., Lansky A. J. et al. A prospective natural-history study of coronary atherosclerosis // New Engl. J. Med. 2011. Vol. 364. P. 226–235.Stone G. W., Maehara A., Lansky A. J. et al. A prospective natural-history study of coronary atherosclerosis // New Engl. J. Med. 2011. Vol. 364. P. 226–235.Tian J., Ren X., Vergallo R. et al. Distinct morphological features of ruptured culprit plaque for acute coronary events compared to those with silent rupture and thin-cap fibroatheroma: a combined optical coherence tomography and intravascular ultrasound study // J. Am. Coll. Cardiol. 2014. Vol. 63. P. 2209–2216.Tian J., Ren X., Vergallo R. et al. Distinct morphological features of ruptured culprit plaque for acute coronary events compared to those with silent rupture and thin-cap fibroatheroma: a combined optical coherence tomography and intravascular ultrasound study // J. Am. Coll. Cardiol. 2014. Vol. 63. P. 2209–2216.Armin Arbab-Zadeh A., Fuster V. The Myth of the “Vulnerable Plaque”// J. Am. Coll. Cardiol. 2015. Vol. 65. P. 846–855.Armin Arbab-Zadeh A., Fuster V. The Myth of the “Vulnerable Plaque”// J. Am. Coll. Cardiol. 2015. Vol. 65. P. 846–855.Yeh R. W., Sidney S., Chandra M. et al. Population trends in the incidence and outcomes of acute myocardial infarction // New Engl. J. Med. 2010. Vol. 362. P. 2155–2165.Yeh R. W., Sidney S., Chandra M. et al. Population trends in the incidence and outcomes of acute myocardial infarction // New Engl. J. Med. 2010. Vol. 362. P. 2155–2165.Jia H., Abtahian F., Aguirre A. D. et al. In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography // J. Am. Coll. Cardiol. 2013. Vol. 62. P. 1748–1758.Jia H., Abtahian F., Aguirre A. D. et al. In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography // J. Am. Coll. Cardiol. 2013. Vol. 62. P. 1748–1758.Braunwald E. Coronary plaque erosion: recognition and management // JACC Cardiovasc. Imaging. 2013. Vol. 6. P. 288–289.Braunwald E. Coronary plaque erosion: recognition and management // JACC Cardiovasc. Imaging. 2013. Vol. 6. P. 288–289.Аrmstrong P. W., Gershlick A. H., Goldstein P. et al. Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction // New Engl. J. Med. 2013. Vol. 368. P. 1379–1387.Аrmstrong P. W., Gershlick A. H., Goldstein P. et al. Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction // New Engl. J. Med. 2013. Vol. 368. P. 1379–1387.Bonaca M. P., Bhatt D. L., Cohen M. et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction // New Engl. J. Med. 2015. Vol. 372. P. 1791–1800.Bonaca M. P., Bhatt D. L., Cohen M. et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction // New Engl. J. Med. 2015. Vol. 372. P. 1791–1800.

The authors declare that there are no conflicts of interest present.